KEY TAKEAWAYS
- The PALETTE phase III trial aimed to evaluate the safety and effectiveness of pazopanib in the real-world treatment of advanced U-LMS.
- The endpoints were response rate, PFS, and safety.
- The study showed promising effects for selected patients, offering survival outcomes similar to those of other studies, but complex side effects require careful monitoring by clinicians.
Rare uterine leiomyosarcoma (U-LMS) needs specialized care and lacks effective targeted therapies, making chemotherapy (CT) the mainstay for advanced cases. So, for this study, researchers aimed to evaluate the safety and effectiveness of pazopanib in the real-world treatment of advanced U-LMS.
They retrospectively analyzed the outcomes of pazopanib in metastatic U-LMS patients at a tertiary oncologic center in Italy. The study evaluated the endpoints of response rate, progression-free survival (PFS), and safety.
About 30 patients diagnosed with metastatic U-LMS were treated with pazopanib. The majority (93%) had a favorable performance status (PS ECOG 0–1), with a median age of 53 years (38–72 years old). Lung metastases were most common (70%), and the median number of prior CT was 3 (range 2–5). All patients initiated pazopanib at 800 mg daily, with 23% requiring dose reduction.
The most frequent grade (G) 3 events were hepatic toxicities(HT), nausea, and vomiting (7%). About 2 patients discontinued treatment due to drug-related toxicities: one for anasarca and one for HT. The disease control rate was 43%, with 19% showing partial responses. Complicated responses, including pneumothorax, intestinal perforation, intestinal occlusion, and hemoptysis due to pulmonary cavitation, were observed in 4 cases.
The overall population had a median PFS of 3 months, while the responders’ subgroup had a median PFS of 7 months (range 4–21). About 4 patients remain on treatment after a median period of 6 months.
The study showed promising effects for selected patients, offering survival outcomes similar to those of other studies, but complex side effects require careful monitoring by clinicians.
Source: https://ijgc.bmj.com/content/33/Suppl_3/A219.1.abstract
Clinical Trial: https://clinicaltrials.gov/study/NCT00753688
Mantiero M, Ducceschi M, Polignano M, Bini M, Lopez S, Cavalli C, Franza A, Rota S, Fabbroni C, Raspagliesi F, Casali PG, Sanfilippo R. Real-life experience of pazopanib in uterine leiomyosarcoma (U-LMS) in a tertiary oncologic center in Italy: evaluation of safety and effectiveness.
